Watson Pharmaceuticals wins groundbreaking FDA case
This article was originally published in Clinica
In a landmark decision with potential implications for devices and diagnostics manufacturers, Watson Pharmaceuticals has been found not to have breached copyright in labelling for a product after the FDA demanded that it follow the wording already permitted for an earlier approved product.
You may also be interested in...ï»¿
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.